- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ANNEXIN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 08:30 | Annexin Pharmaceuticals AB: Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV | 85 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces that the World Health Organization (WHO) has selected vanexin as the proposed International Nonproprietary Name (INN) for the company's drug candidate ANXV.... ► Artikel lesen | |
| 21.07. | Annexin Pharmaceuticals AB: Annexin updates on nine patients treated in NEXUS study | 149 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB announces an update on the patient recruitment status in the NEXUS study. As of today, six patients with retinal vein occlusion (RVO) and three patients with diabetic retinopathy... ► Artikel lesen | |
| 03.07. | Annexin Pharmaceuticals AB: Annexin's rights issue 98 percent subscribed | 219 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen | |
| 23.06. | Annexin Pharmaceuticals AB: Annexin updates on continuous promising data from the NEXUS study - demonstrating improvement of retinal perfusion in both DR and RVO | 235 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB announces an update on the NEXUS study key preliminary clinical findings. To date, treatment with the drug candidate ANXV has not been associated with limiting safety or tolerability... ► Artikel lesen | |
| 15.06. | Annexin Pharmaceuticals AB: The subscription period in Annexin Pharmaceuticals' rights issue begins today | 219 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen | |
| 12.06. | Listing of subscription rights and paid subscription shares of Annexin Pharmaceuticals AB | 300 | GlobeNewswire | With effect from June 15, 2026, the subscription rights in Annexin Pharmaceuticals AB will be traded on First North Growth Market. Trading will continue up until and including June 29, 2026.
... ► Artikel lesen | |
| 10.06. | Annexin Pharmaceuticals AB: Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue | 195 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen | |
| 09.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.06.2026 | 772 | Xetra Newsboard | Das Instrument G85 CA35958L1013 FUERTE METALS CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 09.06.2026 und ex Kapitalmassnahme am 10.06.2026 The instrument G85 CA35958L1013 FUERTE METALS CORP.... ► Artikel lesen | |
| 03.06. | Annexin Pharmaceuticals AB: Annexin resolves a rights issue of approximately SEK 20 million, secured to approximately 60 percent, with an overallotment option of up to approximately SEK 5 million | 215 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen | |
| 21.05. | Annexin Pharmaceuticals AB: Annexin investigates a three-day ANXV treatment regimen in patients with RVO | 224 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces a shortening of the ANXV treatment regimen from five to three days at the same dose level. A three-day treatment is expected to strengthen the commercial value... ► Artikel lesen | |
| 11.05. | Annexin Pharmaceuticals AB: Annexin receives clinical trial approval in Germany, widening patient recruitment in the NEXUS study | 234 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces that the company has received an approval for a clinical trial with the drug candidate ANXV by the German Medicines Agency Bundesinstitut für Arzneimittel... ► Artikel lesen | |
| 22.04. | Annexin Pharmaceuticals AB: Annexin accelerates patient recruitment - five patients treated | 262 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces an update on patient recruitment in the ongoing Phase 2a/Proof of Concept study NEXUS, investigating the drug candidate ANXV in retinal vein occlusion (RVO)... ► Artikel lesen | |
| 13.04. | Annexin Pharmaceuticals AB: Annexin secures financing through bridge loan facility and plans a rights issue of approximately SEK 20 million during the summer of 2026 | 230 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB (publ) today announces that the company has secured bridge financing of approximately SEK 4 million and intends to carry out a rights issue of approximately SEK 20 million... ► Artikel lesen | |
| 04.02. | Annexin Pharmaceuticals AB: Favourable findings in Annexin's ongoing Phase 2a study in Diabetic Retinopathy and Retinal Vein Occlusion | 651 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces favourable findings in the company's ongoing Proof of Concept Phase 2a study with the drug candidate ANXV in Diabetic Retinopathy (DR) and Retinal Vein Occlusion... ► Artikel lesen | |
| 05.12.25 | Annexin Pharmaceuticals AB: First patients treated in Annexin's Phase 2a study in diabetic retinopathy and RVO | 299 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces that the first two patients have been dosed in the company's Proof of Concept Phase 2a study with the drug candidate ANXV in diabetic retinopathy (DR) and... ► Artikel lesen | |
| 16.09.25 | Annexin Pharmaceuticals AB: Annexin appoints world-leading ophthalmology experts to Medical Advisory Board | 311 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB has appointed a Medical Advisory Board in Ophthalmology. The independent clinical experts in the Board will act as key advisors to the Annexin team advancing the clinical... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMYLYX PHARMACEUTICALS | 38,600 | 0,00 % | Kaum zu fassen: Die unglaubliche Biotech-Story von Amylyx Pharmaceuticals | Der Biotech-Sektor ist immer wieder für faustdicke Überraschungen gut - sowohl negativ als auch positiv. Bei Amylyx Pharmaceuticals gibt es am Dienstag keine zwei Meinungen: Die Aktie des Biotech-Unternehmens... ► Artikel lesen | |
| MODERNA | 133,38 | -10,85 % | Termin-Börse daily: Unser Moderna-Call explodiert um 420 % - hier ist der Grund | MODERNA schießt heute vorbörslich um rund 100 % nach oben. Auslöser sind positive Phase-III-Daten für den gemeinsam mit MERCK entwickelten mRNA-Krebsimpfstoff gegen Melanome. Nach Angaben des Unternehmens... ► Artikel lesen | |
| CG ONCOLOGY | 80,68 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,070 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| NURIX THERAPEUTICS | 27,790 | 0,00 % | Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,72 | 0,00 % | AbbVie schließt Anleiheemission über 8,0 Mrd. US-Dollar zur Finanzierung der Übernahme von Apogee Therapeutics ab | ||
| TARSUS PHARMACEUTICALS | 73,44 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position | Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of... ► Artikel lesen | |
| IMMUNOME | 29,840 | +0,05 % | Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027 | ||
| BIONTECH | 94,15 | -2,74 % | Schlafender Biotech-Riese vor der nächsten Wachstumsphase? BioNTech, Emyria und die neue Macht der Datenplattformen | ||
| RECURSION PHARMACEUTICALS | 3,495 | -0,14 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 386,17 | -0,01 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| KYMERA THERAPEUTICS | 127,25 | -0,05 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| ZENAS BIOPHARMA | 31,200 | -0,16 % | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ERASCA | 18,065 | 0,00 % | Stifel reiterates Buy rating on Erasca stock, $30 target | ||
| VOR BIOPHARMA | 23,580 | 0,00 % | Vor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of... ► Artikel lesen |
Das Unternehmen ANNEXIN PHARMACEUTICALS AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,010 (+0,85 %) liegt der Kurs bei 1,180 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ANNEXIN PHARMACEUTICALS AB finden Sie auf Wallstreet Online.